Amplitude Surgical

Earnings Release • Apr 17, 2025

Amplitude Surgical - 9-months consolidated sales for FY 2024-25 of €83.8m, up +6.4% at constant exchange rates

• Sales up +6.6% at constant exchange rates in Q3 FY 2024-25
• Consolidated sales for 9 months up+ 6.4% at constant exchange rates to €83.8m
• Good momentum in France: sales up +4.7% over 9 months
• Strong international business: sales up +11.1% at constant exchange rates over 9 months

Valence, April 17, 2025, 6:00 pm CEST - Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its consolidated sales for the third quarter of the 2024-25 financial year.

Olivier Jallabert, Chief Executive Officer of Amplitude Surgical, comments: "In the first 9 months of the 2024-25 financial year, Amplitude Surgical continued its growth trajectory, posting sales growth of +6.4% at constant exchange rates compared with the same period last year. Business grew both in France, with an increase of +4.7%, and internationally, with growth of +11.1% at constant exchange rates."

Sales 9M 2024-25 In K€ - IFRS	31/03/2025	31/03/2024	Change at current exchange rates	Change at constant exchange rates
Knee and hip activities	83 813	79 614	5,3%	6,4%
Total	83 813	79 614	5,3%	6,4%
Sales Q3 2024-25 In K€ - IFRS	31/03/2025	31/03/2024	Change at current exchange rates	Change at constant exchange rates
Knee and hip activities	32 310	30 557	5,7%	6,6%

Consolidated sales 9 months of FY 2024-25

For the first 9 months (July 2004 - March 2025) of the 2024-25 financial year, Amplitude Surgical sales came to €83.8 million, up +5.3% and +6.4% at constant exchange rates.

Over the 9 months, sales of knees and hips rose by +4.7% in France and by +11.1% at constant exchange rates outside France. Within the international perimeter, international distributors were up +6.6%, and the Group's international subsidiaries recorded a +7.1% increase at current exchange rates, and a +12.6% increase at constant exchange rates.

For the third quarter 2024-25, growth was 6.6% at constant exchange rates, in line with the Group's 9 month performance, with a 4.8% increase in France, a 12.4% increase at constant exchange rates for the Group's international subsidiaries, and a 12.3% increase for international distributors.

Amplitude Surgical's direct sales (French market and international subsidiaries), which account for almost 93% of total Group sales, rose by +6.4% at constant exchange rates.

France accounted for around 72% of Group sales in the first 9 months of the 2024-25 financial year.

International subsidiaries reported growth at constant exchange rates in Belgium, Australia, Brazil and South Africa, while sales in Germany and Switzerland were down.

Next press release:

Annual sales 2024-25: Thursday, July 24, 2025, after market close.

About Amplitude Surgical

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery, covering the main pathologies affecting the hip and knee. Working in close collaboration with surgeons, Amplitude Surgical develops numerous high value-added innovations to best meet the needs of patients, surgeons and care facilities. A leading player in France, Amplitude Surgical is expanding internationally through its subsidiaries and a network of agents and exclusive distributors in over 30 countries. At June 30, 2024, Amplitude Surgical had 428 employees and sales of nearly 106.0 million euros.

Contact Amplitude Surgical Chief Financial Officer Dimitri Borchtch finances@amplitude-surgical.com 04 75 41 87 41

NewCap Investor Relations Thomas Grojean amplitude@newcap.eu 01 44 71 94 94

NewCap Media Relations Nicolas Merigeau amplitude@newcap.eu 01 44 71 94 98